Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Pharmacological therapies for acute cardiogenic shock ; Farmakološko liječenje u akutnom kardiogenom šoku

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Skorić, Boško
    • بيانات النشر:
      Sveučilište u Zagrebu. Medicinski fakultet. KATEDRA ZA INTERNU MEDICINU.
      University of Zagreb. School of Medicine. Department of Internal Medicine.
    • الموضوع:
      2021
    • Collection:
      Croatian Digital Theses Repository (National and University Library in Zagreb)
    • نبذة مختصرة :
      Cardiogenic shock (CS) is a life threatening condition, a state of end-organ hypoperfusion, caused by cardiac failure leading to low cardiac output and inability of cardiovascular system to provide adequate flow of oxygen-rich blood to body-extremities and vital organs. This is a clinical syndrome characterized by a systemic hypotension <90 mmHg, and signs of tissue hypoperfusion, usually as a sequela of an acute myocardial infarction. Cardiogenic shock can also arise from nonischemic causes, like myocarditis, endocarditis and pericardial tamponade. The incidence of cardiogenic shock is in decline, which reflects increased use of coronary reperfusion strategies for MI, including primary percutaneous coronary intervention (PCI) and fibrinolytic therapy which by limiting the infarct size also reduces the risk of shock development. Initial medical treatment includes IVFs, inotropes and vasopressors. Inotropes are divided into subgroups, according to their mechanism of action we distinguish beta-agonists, phosphodiesterase III inhibitors and Ca2+ sensitizers. Inotropes act on heart contractility, vasopressors increase vasoconstriction, consequently causing increase in mean arterial pressure (MAP) and Ca2+ sensitizers, among other pharmacological agents, are used to increase sensitivity of myocardiocytes on intracellular Ca2+ level. Pathophysiology of CS is not fully understood, it is a vicious cycle: when it is caused by infarction, ischemia leads to myocardial dysfunction which causes left ventricular systolic and diastolic dysfunction manifested with elevated left ventricular end diastolic pressure (LVEDP), decreased cardiac output and decreased coronary perfusion. Systemic hypoperfusion causes compensatory vasoconstriction and tachycardia which increases myocardial oxygen demand and subsequently worsens myocardial ischemia. This self-perpetuating cycle leads to progressive myocardial dysfunction and finally to the multi-organ failure unless it is interrupted by an adequate therapy. CS is an emergency condition ...
    • File Description:
      application/pdf
    • Relation:
      https://zir.nsk.hr/islandora/object/mef:3874; https://urn.nsk.hr/urn:nbn:hr:105:563021; https://repozitorij.unizg.hr/islandora/object/mef:3874; https://repozitorij.unizg.hr/islandora/object/mef:3874/datastream/PDF
    • الدخول الالكتروني :
      https://zir.nsk.hr/islandora/object/mef:3874
      https://urn.nsk.hr/urn:nbn:hr:105:563021
      https://repozitorij.unizg.hr/islandora/object/mef:3874
      https://repozitorij.unizg.hr/islandora/object/mef:3874/datastream/PDF
    • Rights:
      http://rightsstatements.org/vocab/InC/1.0/ ; info:eu-repo/semantics/openAccess
    • الرقم المعرف:
      edsbas.2E0FBAFD